GliaPharm Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $5.23M

  • Investors
  • 5

GliaPharm General Information

Description

Developer of neurological and psychiatric disorders treatments and therapies designed to target glial cells and brain metabolism to treat diseases. The company specializes in the research and development of novel therapies to treat and prevent neurological diseases by targeting glial cells, the support cells of neurons, to sustain and enhance brain metabolism in pathological conditions, enabling patients with neurological disorders, pharmaceutical researchers, and clinicians worldwide to explore innovative neuroprotective therapies, maintain cognitive functions, and advance treatment options for brain-related conditions.

Contact Information

Website
www.gliapharm.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Campus Biotech
  • Ch. des Mines 9
  • 1202 Geneva
  • Switzerland
+41 022
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • Campus Biotech
  • Ch. des Mines 9
  • 1202 Geneva
  • Switzerland
+41 022

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GliaPharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Grant 15-Dec-2023 $5.23M Completed Generating Revenue
6. Secondary Transaction - Private Completed Clinical Trials - Phase 1
5. Accelerator/Incubator Completed Clinical Trials - Phase 1
4. Later Stage VC (Series A) 28-Oct-2022 Cancelled Clinical Trials - Phase 1
3. Later Stage VC 04-Jul-2022 Completed Clinical Trials - Phase 1
2. Early Stage VC 25-May-2020 $2.06M $2.16M Completed Clinical Trials - Phase 1
1. Accelerator/Incubator 23-May-2017 $100K $100K Completed Clinical Trials - Phase 1
To view GliaPharm’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

GliaPharm Patents

  • 47

    Total Documents Applications and Grants

  • Total Patents Families

  • 22

    Granted

  • 10

    Pending

  • Expiring in next 12 mo

GliaPharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023355674-A1 Lactate enhancing compounds and uses thereof Pending 03-Oct-2022
EP-4598533-A1 Lactate enhancing compounds and uses thereof Pending 03-Oct-2022
US-20260125357-A1 Lactate enhancing compounds and uses thereof Pending 03-Oct-2022
WO-2024074436-A1 Lactate enhancing compounds and uses thereof Inactive 03-Oct-2022
ES-2981840-T3 Isoquinoline derivatives for use in the treatment of glut1 deficiency syndrome Active 30-Dec-2019 A61K31/47
To view GliaPharm’s complete patent history, request access »

GliaPharm Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GliaPharm Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alzheimers Drug Discovery Foundation Not-For-Profit Venture Capital
Fongit Accelerator/Incubator Minority
Gliaven Corporation Minority
MassChallenge Accelerator/Incubator
Ecole Polytechnique Federale de Lausanne University Minority
To view GliaPharm’s complete investors history, request access »

Ready to get started?

Request a free trial

GliaPharm FAQs

  • When was GliaPharm founded?

    GliaPharm was founded in 2016.

  • Where is GliaPharm headquartered?

    GliaPharm is headquartered in Geneva, Switzerland.

  • What is the size of GliaPharm?

    GliaPharm has 6 total employees.

  • What industry is GliaPharm in?

    GliaPharm’s primary industry is Drug Discovery.

  • Is GliaPharm a private or public company?

    GliaPharm is a Private company.

  • What is GliaPharm’s current revenue?

    The current revenue for GliaPharm is .

  • How much funding has GliaPharm raised over time?

    GliaPharm has raised $2.26M.

  • Who are GliaPharm’s investors?

    Alzheimers Drug Discovery Foundation, Fongit, Gliaven, MassChallenge, and Ecole Polytechnique Federale de Lausanne have invested in GliaPharm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process